Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers

B. D. Kirkpatrick, Robin McKenzie, J. Patrick O'Neill, Catherine J. Larsson, A. Louis Bourgeois, Janet Shimko, Matthew Bentley, Jill Makin, Steve Chatfield, Zoë Hindle, Christine Fidler, Brad E. Robinson, Cassandra H. Ventrone, Nivedita Bansal, Colleen M. Carpenter, Deborah Kutzko, Sandra Hamlet, Casey Lapointe, David N. Taylor

Research output: Contribution to journalArticle

Abstract

Salmonella enterica serovar Typhi strains with mutations in the Salmonella pathogenicity island-2 (SPI-2) may represent an effective strategy for human vaccine development, and a vectoring system for heterologous antigens. S. Typhi (Ty2 aroC-ssaV-) M01ZH09 is an attenuated, live, oral typhoid vaccine harboring defined deletion mutations in ssaV, which encodes an integral component in the SPI-2 type III secretion system (TTSS), as well as a mutation in an aromatic biosynthetic pathway needed for bacterial growth in vivo (aroC). SPI-2 mutant vaccines have yet to be evaluated in a large, randomized human trial. A simplified or single-oral dose oral typhoid vaccine using the SPI-2 strategy would offer significant advantages over the currently licensed typhoid vaccines. We performed a double-blinded, placebo-controlled, dose-escalating clinical trial in 60 healthy adult volunteers to determine the tolerability and immunogenicity of a single dose of M01ZH09. Three groups of 20 healthy adult volunteers were enrolled; 16 in each group received a single oral dose of the freeze-dried vaccine at 5 × 107, 5 × 108 or 5 × 109 CFU in a bicarbonate buffer. Four volunteers in each cohort received placebo in the same buffer. Adverse events were infrequent and not statistically different between vaccine and placebo recipients, although two subjects in the mid-range dose and three subjects in the highest dose had temperature measurements >37.5°C. No blood or urine cultures were positive for M01ZH09, and fecal shedding was brief. The immune response was dose-related; the highest vaccine dose (5 × 109 CFU) was the most immunogenic. All tested subjects receiving the highest dose had a significant ASC response (mean 118 spots/106 cells). A ≥4-fold increase in antibody titer for S. Typhi LPS or flagellin was detected in 75% of volunteers in the highest-dose cohort by day 28. The SPI-2 mutant vaccine, M01ZH09, is a promising typhoid vaccine candidate and deserves further study as a vectoring system for heterologous vaccine antigens.

Original languageEnglish (US)
Pages (from-to)116-123
Number of pages8
JournalVaccine
Volume24
Issue number2
DOIs
StatePublished - Jan 12 2006

Keywords

  • Oral vaccines
  • Salmonella pathogenicity island
  • Typhoid vaccines

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers'. Together they form a unique fingerprint.

  • Cite this

    Kirkpatrick, B. D., McKenzie, R., O'Neill, J. P., Larsson, C. J., Bourgeois, A. L., Shimko, J., Bentley, M., Makin, J., Chatfield, S., Hindle, Z., Fidler, C., Robinson, B. E., Ventrone, C. H., Bansal, N., Carpenter, C. M., Kutzko, D., Hamlet, S., Lapointe, C., & Taylor, D. N. (2006). Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine, 24(2), 116-123. https://doi.org/10.1016/j.vaccine.2005.08.008